Aziyo Biologics
Market Cap
US$133.3m
Last Updated
2021/04/12 23:15 UTC
Data Sources
Company Financials +
Executive Summary
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with concerning outlook.
Similar Companies
Share Price & News
How has Aziyo Biologics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AZYO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: AZYO's weekly volatility (10%) has been stable over the past year.
Market Performance
7 Day Return
-4.6%
AZYO
-3.6%
US Biotechs
0.9%
US Market
1 Year Return
n/a
AZYO
29.2%
US Biotechs
57.9%
US Market
Return vs Industry: Insufficient data to determine how AZYO performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AZYO performed against the US Market.
Shareholder returns
| AZYO | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.6% | -3.6% | 0.9% |
| 30 Day | -5.8% | -5.2% | 2.3% |
| 90 Day | -10.1% | -7.5% | 6.3% |
| 1 Year | n/a | 31.2%29.2% | 60.8%57.9% |
| 3 Year | n/a | 26.2%20.4% | 64.5%53.9% |
| 5 Year | n/a | 40.1%29.6% | 120.9%96.4% |
Long-Term Price Volatility Vs. Market
How volatile is Aziyo Biologics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall St
Are Institutions Heavily Invested In Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Shares?Valuation
Is Aziyo Biologics undervalued compared to its fair value and its price relative to the market?
6.4x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AZYO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AZYO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AZYO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AZYO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AZYO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AZYO is overvalued based on its PB Ratio (6.4x) compared to the US Biotechs industry average (3.7x).
Future Growth
How is Aziyo Biologics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
53.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AZYO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AZYO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AZYO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AZYO's revenue (16.8% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: AZYO's revenue (16.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AZYO's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Aziyo Biologics performed over the past 5 years?
-111.8%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: AZYO is currently unprofitable.
Growing Profit Margin: AZYO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if AZYO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare AZYO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AZYO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: AZYO has a negative Return on Equity (-104.77%), as it is currently unprofitable.
Financial Health
How is Aziyo Biologics's financial position?
Financial Position Analysis
Short Term Liabilities: AZYO's short term assets ($59.7M) exceed its short term liabilities ($26.8M).
Long Term Liabilities: AZYO's short term assets ($59.7M) exceed its long term liabilities ($35.2M).
Debt to Equity History and Analysis
Debt Level: AZYO's debt to equity ratio (147.1%) is considered high.
Reducing Debt: Insufficient data to determine if AZYO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AZYO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AZYO has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 41.1% each year.
Dividend
What is Aziyo Biologics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AZYO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AZYO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AZYO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AZYO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AZYO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.5yrs
Average management tenure
CEO
Ron Lloyd (59 yo)
2.83yrs
Tenure
US$689,215
Compensation
Mr. Ronald K. Lloyd, also known as Ron, has been President, Chief Executive Officer and Director of Aziyo Biologics, Inc. from June 2018. Mr. Lloyd served as Executive Vice President and President of Hospi...
CEO Compensation Analysis
Compensation vs Market: Ron's total compensation ($USD689.22K) is above average for companies of similar size in the US market ($USD512.33K).
Compensation vs Earnings: Insufficient data to compare Ron's compensation with company performance.
Leadership Team
Experienced Management: AZYO's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
Experienced Board: AZYO's board of directors are considered experienced (4.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: AZYO only recently listed within the past 12 months.
Top Shareholders
Company Information
Aziyo Biologics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Aziyo Biologics, Inc.
- Ticker: AZYO
- Exchange: NasdaqGM
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$133.349m
- Shares outstanding: 10.23m
- Website: https://www.aziyo.com
Number of Employees
Location
- Aziyo Biologics, Inc.
- 12510 Prosperity Drive
- Suite 370
- Silver Spring
- Maryland
- 20904
- United States
Listings
Biography
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, an...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/12 23:15 |
| End of Day Share Price | 2021/04/12 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.